Literature DB >> 14645349

Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour.

A Etges1, D S Pinto, L P Kowalski, F A Soares, V C Araújo.   

Abstract

BACKGROUND: Salivary duct carcinoma (SDC) is considered to be a distinct malignancy of the major salivary glands, because of its highly aggressive behaviour, and the high rate of recurrence, metastasis, and disease related death. AIMS: To investigate expression of the proteins involved in the retinoblastoma (pRb) and p53 pathways, which control cell cycle progression at the G1/S checkpoint, and also expression of the c-erbB-2 oncoprotein in SDCs.
METHODS: Using a streptavidin-biotin method, five cases of SDC were evaluated immunohistochemically for the presence of cyclin D1, CDK4 (cyclin dependent kinase 4), p16 (CDK2A), pRb (retinoblastoma protein), E2F-1, p53, mdm2 (murine double minute 2), bcl-2, and the c-erbB-2 oncoprotein to determine whether there was a correlation between the expression of these proteins and patient outcome.
RESULTS: All of the cases showed deregulation of the pRb and p53 pathways. Of the five patients analysed, only the patient with longterm survival (10 years) was not positive for c-erbB-2 expression.
CONCLUSIONS: c-erbB-2 overexpression was associated with a poor prognosis. Aggressive behaviour, recurrence, and metastatic potential do not appear to be related to cell cycle deregulation, but seem to be associated with the c-erbB-2 oncoprotein, which is involved in matrix degradation and proteolitic activity, in addition to increases in vessel permeability, endothelial cell growth, proliferation, migration, and differentiation. There was a correlation between c-erbB-2 oncoprotein expression and aggressive behaviour in SDCs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645349      PMCID: PMC1770135          DOI: 10.1136/jcp.56.12.914

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  45 in total

Review 1.  Control of the cell cycle and apoptosis.

Authors:  A S Lundberg; R A Weinberg
Journal:  Eur J Cancer       Date:  1999-04       Impact factor: 9.162

2.  Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours.

Authors:  N Kamio
Journal:  Virchows Arch       Date:  1996-05       Impact factor: 4.064

Review 3.  Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases.

Authors:  J E Lewis; B C McKinney; L H Weiland; J A Ferreiro; K D Olsen
Journal:  Cancer       Date:  1996-01-15       Impact factor: 6.860

4.  Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; J Shaw; J E Roy; J Koh; D N Louis
Journal:  Lab Invest       Date:  1999-09       Impact factor: 5.662

5.  Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.

Authors:  M Tan; J Yao; D Yu
Journal:  Cancer Res       Date:  1997-03-15       Impact factor: 12.701

6.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

7.  Regulation of p53 stability by Mdm2.

Authors:  M H Kubbutat; S N Jones; K H Vousden
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

8.  Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands.

Authors:  K J Cho; S S Lee; Y S Lee
Journal:  Head Neck       Date:  1999-08       Impact factor: 3.147

9.  Salivary duct carcinoma: clinicopathological and immunohistochemical studies.

Authors:  E Martinez-Barba; J A Cortes-Guardiola; A Minguela-Puras; A Torroba-Caron; S Mendez-Trujillo; J Bermejo-Lopez
Journal:  J Craniomaxillofac Surg       Date:  1997-12       Impact factor: 2.078

10.  Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma.

Authors:  A Felix; A K El-Naggar; M F Press; N G Ordonez; I Fonseca; S L Tucker; M A Luna; J G Batsakis
Journal:  Hum Pathol       Date:  1996-06       Impact factor: 3.466

View more
  25 in total

1.  Breast metastasis of salivary duct carcinoma in a patient: a case report.

Authors:  Shuangshuang Guo; Jun Yao
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  Dysregulation of the Rb pathway in recurrent pleomorphic adenoma of the salivary glands.

Authors:  Ana Amélia de Souza; Albina Altemani; Fabricio Passador-Santos; Cecilia Pedroso Turssi; Ney Soares de Araujo; Vera Cavalcanti de Araújo; Andresa Borges Soares
Journal:  Virchows Arch       Date:  2015-07-09       Impact factor: 4.064

3.  Management and outcome of salivary duct carcinoma in major salivary glands.

Authors:  Elina Salovaara; Olli Hakala; Leif Bäck; Petri Koivunen; Kauko Saarilahti; Fabricio Passador-Santos; Ilmo Leivo; Antti A Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-03-22       Impact factor: 2.503

Review 4.  Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature.

Authors:  Abdullah Mislat Alotaibi; Mohammed Ali Alqarni; Abdelrahman Alnobi; Bassel Tarakji
Journal:  J Clin Diagn Res       Date:  2015-02-01

5.  Parotid carcinoma: Current diagnostic workup and treatment.

Authors:  Vincent L M Vander Poorten; Francis Marchal; Sandra Nuyts; Paul M J Clement
Journal:  Indian J Surg Oncol       Date:  2010-11-21

6.  Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.

Authors:  Michelle D Williams; Dianna B Roberts; Merrill S Kies; Li Mao; Randal S Weber; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

7.  Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.

Authors:  Gerald S Falchook; Scott M Lippman; Christel C Bastida; Razelle Kurzrock
Journal:  Head Neck       Date:  2013-10-19       Impact factor: 3.147

Review 8.  A review: Immunological markers for malignant salivary gland tumors.

Authors:  P C Anila Namboodiripad
Journal:  J Oral Biol Craniofac Res       Date:  2014-08-28

Review 9.  Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved.

Authors:  Markus Stenner; J Peter Klussmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-04       Impact factor: 2.503

10.  Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy.

Authors:  Guanglin Liu; Haiqing Zheng; Zhibing Zhang; Zhiqiang Wu; Huaping Xiong; Jun Li; Libing Song
Journal:  BMC Cancer       Date:  2010-09-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.